# US 2019/0314368 A1 · Oral solid preparation and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314368 A1
- Document ID: US20190314368A1
- Status: Published application
- Kind: A1
- Application number: 16/317,508
- Filed: 2017-07-28
- Published: 2019-10-17
- Earliest claimed: 2016-07-29
- Assignees: Wuhan Ll Science and Technology Development Co., Ltd.; Wuhan Qr Pharmaceuticals Co., Ltd.
- Applicants: Wuhan Ll Science and Technology Development Co., Ltd.; Wuhan Qr Pharmaceuticals Co., Ltd.
- Inventors: Lei LIANG; Yongkai CHEN; Liu HU; Wei FENG; Chaodong WANG
- Web page: https://patentgrep.com/patent/US20190314368A1

## CPC

- A61K 31/42: Oxazoles
- A61K 31/497: containing further heterocyclic rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/45: having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61P 9/12: Antihypertensives
- C07D 413/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disintegrates rapidly, increasing dissolution rate thereof, thereby improving bioavailability. In particular, it is possible to solve the problem that an active material (active ingredient), which is high hygroscopic and becomes sticky after moisture absorption, can not be effectively disintegrated by conventional disintegrants. The present invention further relates to a use of the oral solid preparation in preparing an angiotensin II receptor antagonist or a use thereof in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.

## Claims

### Claim 1

An oral solid preparation comprising an active ingredient, the active ingredient comprises a crystalline form of the compound of formula (A):
preferably, the oral solid preparation further comprises a disintegrant, a disintegrant assistant, an excipient and a lubricant.

### Claim 2 (depends on 1)

The oral solid preparation according to claim 1, wherein the crystalline form of the compound of formula (A) is selected from at least one from the group consisting of crystalline form I, crystalline form II, crystalline form III and crystalline form IV;
preferably, the crystalline form of the compound of formula (A) is selected from the crystalline form I, the crystalline form II or a mixture thereof;
for example, a weight ratio of the crystalline form I to the crystalline form II may be from 1:99 to 99:1, such as from 5:95 to 95:5; as an example, the weight ratio of the crystalline form I to the crystalline form II may be from 1:9 to 9:1, from 2:8 to 8:2, from 3:7 to 7:3, from 4:6 to 6:4 or 5:5.

### Claim 3 (depends on 2)

The oral solid preparation according to claim 2, wherein,
an X-ray powder diffraction pattern of the crystalline form I comprises characteristic peaks at diffraction angles (2-Theta) of 5.3±0.2°, 8.6±0.2°; preferably, the X-ray powder diffraction pattern of the crystalline form I further comprises characteristic peaks at diffraction angles (2-Theta) of 13.3±0.2°, 20.1±0.2°; further preferably, the X-ray powder diffraction pattern of the crystalline form I further comprises characteristic peaks at diffraction angles (2-Theta) of 6.3±0.2°, 10.6±0.2°, 26.3±0.2°; more preferably, the X-ray powder diffraction pattern of the crystalline form I further comprises characteristic peaks at diffraction angles (2-Theta) of 12.7±0.2°; most preferably, the X-ray powder diffraction pattern of the crystalline form I is substantially as shown in FIG. 1;
an X-ray powder diffraction pattern of the crystalline form II comprises characteristic peaks at diffraction angles (2-Theta) of 4.7±0.2°; preferably, the X-ray powder diffraction pattern of the crystalline form II further comprises characteristic peaks at diffraction angles (2-Theta) of 7.3±0.2°, 9.6±0.2°, 15.2±0.2°, 26.3±0.2°; further preferably, the X-ray powder diffraction pattern of the crystalline form II further comprises characteristic peaks at diffraction angles (2-Theta) of 11.8±0.2°, 24.6±0.2°; more preferably, the X-ray powder diffraction pattern of the crystalline form II further comprises characteristic peaks at diffraction angles (2-Theta) of 22.6±0.2°; most preferably, the X-ray powder diffraction pattern of the crystalline form II is substantially as shown in FIG. 2;
an X-ray powder diffraction pattern of the crystalline form III comprises characteristic peaks at diffraction angles (2-Theta) of 5.2±0.2°, 8.0±0.2°; preferably, the X-ray powder diffraction pattern of the crystalline form III further comprises characteristic peaks at diffraction angles (2-Theta) of 12.4±0.2°, 13.6±0.2°; further preferably, the X-ray powder diffraction pattern of the crystalline form III further comprises characteristic peaks at diffraction angles (2-Theta) of 19.2±0.2°; more preferably, the X-ray powder diffraction pattern of the crystalline form III further comprises characteristic peaks at diffraction angles (2-Theta) of 10.3±0.2°, 12.2±0.2°, 21.4±0.2°; most preferably, the X-ray powder diffraction pattern of the crystalline form III is substantially as shown in FIG. 3;
an X-ray powder diffraction pattern of the crystalline form IV comprises characteristic peaks at diffraction angles (2-Theta) of 7.4±0.2°, 14.7±0.2°, 16.0±0.2°; preferably, the X-ray powder diffraction pattern of the crystalline form IV further comprises characteristic peaks at diffraction angles (2-Theta) of 8.4±0.2°, 22.6±0.2°, 23.2±0.2°, 29.7±0.2°; more preferably, the X-ray powder diffraction pattern of the crystalline form IV further comprises characteristic peaks at diffraction angles (2-Theta) of 24.0±0.2°; most preferably, the X-ray powder diffraction pattern of the crystalline form IV is substantially as shown in FIG. 4.

### Claim 4 (depends on 1)

The oral solid preparation according to claim 1, wherein,
a content of the active ingredient is about 5-50% by weight, a content of the disintegrant is about 1-20% by weight, a content of the disintegrant assistant is about 0.1-35% by weight, a content of the excipient is about 20-80% by weight, a content of the lubricant is about 0.25-10% by weight, and a weight ratio of the disintegrant to the disintegrant assistant is from 10:1 to 1:10;
preferably, the content of the active ingredient is about 8-30% by weight, the content of the disintegrant is about 2-18% by weight, the content of the disintegrant assistant is about 0.5-30% by weight, the content of the excipient is about 30-80% by weight, the content of the lubricant is about 0.5-8% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 8:1 to 1:8;
further preferably, the content of the active ingredient is about 10-20% by weight, the content of the disintegrant is about 4-15% by weight, the content of the disintegrant assistant is about 1-25% by weight, the content of the excipient is about 50-80% by weight, the content of the lubricant is about 1-5% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 5:1 to 1:5;
further preferably, the content of the active ingredient is about 12-16% by weight, the content of the disintegrant is about 6-10% by weight, the content of the disintegrant assistant is about 2-5% by weight, the content of the excipient is about 65-78% by weight, and the content of the lubricant is about 2-4% by weight;
more preferably, the oral solid preparation is a tablet.

### Claim 5 (depends on 4)

The oral solid preparation according to claim 4, wherein the disintegrant is a hygroscopic swelling type disintegrant;
preferably, the hygroscopic swelling type disintegrant is selected from at least one of the group consisting of dry starch, croscarmellose sodium, sodium carboxymethylcellulose, calcium carboxymethylcellulose, sodium carboxymethyl starch, methylcellulose, low degree substituted hydroxylpropyl cellulose, crospovidone, chitosan and microcrystalline cellulose.

### Claim 6 (depends on 4)

The oral solid preparation according to claim 4, wherein the disintegrant assistant is a soluble small molecule or a gas generating type salt;
preferably, the gas generating salt is selected from at least one of the group consisting of a carbonate and a hydrogencarbonate; more preferably, the gas generating salt is selected from at least one of the group consisting of sodium carbonate, calcium carbonate, potassium carbonate, calcium magnesium carbonate, zinc carbonate, magnesium carbonate, ammonium carbonate, sodium glycinate carbonate, sodium sesquicarbonate, sodium hydrogencarbonate, calcium hydrogencarbonate, potassium hydrogencarbonate and ammonium hydrogencarbonate;
preferably, the soluble small molecule is selected from at least one of the group consisting of sodium chloride, glucose, fructose, xylitol; more preferably, the soluble small molecule is selected from at least one of the group consisting of sodium chloride and glucose.

### Claim 7 (depends on 4)

The oral solid preparation according to claim 4, wherein the excipient is selected from at least one of the group consisting of starch, lactose, mannitol, cellulose lactose, microcrystalline cellulose, calcium hydrogen phosphate and mannitol-starch complex;
the lubricant is selected from at least one of the group consisting of talcum powder, magnesium stearate, calcium stearate, colloidal silica, hydrated silica, sodium octadecyl fumarate, polyethylene glycol, sodium stearyl fumarate, glyceryl monostearate and hydrogenated vegetable oil.

### Claim 8 (depends on 4)

The oral solid preparation according to claim 4, wherein the oral solid preparation further comprises a binder;
preferably, the binder is selected from at least one of the group consisting of starch and derivatives thereof (including but not limited to starch, pregelatinized starch, dextrin and maltodextrin, etc.), cellulose derivatives (including but not limited to methylcellulose, carboxy methylcellulose sodium, hydroxypropylcellulose, hypromellose, ethylcellulose and microcrystalline cellulose, etc.), natural and synthetic rubbers (including but not limited to gelatin, gum arabic, locust gum and peach glue, etc.), polyethylene glycol, povidone, glycerol dibehenate, carbomer, polyvinyl alcohol, poly(meth)acrylic resin, sugar alcohols (including but not limited to sucrose, liquid glucose and maltose alcohol, etc.), corn gluten, sodium alginate, and monolaurate;
more preferably, a content of the binder is about 0-15% by weight.

### Claim 9 (depends on 2)

A tablet comprising a crystalline form I, a crystalline form II or a mixture thereof in any ratio as an active ingredient, mannitol as an excipient, croscarmellose sodium as a disintegrant, sodium hydrogencarbonate as a disintegrant assistant, and magnesium stearate as a lubricant;
wherein the crystalline form I and the crystalline form II are defined according to claim 2;
preferably, a content of the active ingredient is about 5-50% by weight, a content of the croscarmellose sodium is about 1-20% by weight, a content of the sodium hydrogencarbonate is about 0.1-35% by weight, a content of the mannitol is about 20-80% by weight, a content of the magnesium stearate is about 0.25-10% by weight, and a weight ratio of the disintegrant to the disintegrant assistant is from 10:1 to 1:10;
further preferably, the content of the active ingredient is about 8-30% by weight, the content of the croscarmellose sodium is about 2-18%, the content of the sodium hydrogencarbonate is about 0.5-30% by weight, the content of the mannitol is about 30-80% by weight, and the content of the magnesium stearate is about 0.5-8% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 8:1 to 1:8;
more preferably, the content of the active ingredient is about 10-20% by weight, the content of the croscarmellose sodium is about 4-15% by weight, the content of the sodium hydrogencarbonate is about 1-25% by weight, the content of the mannitol is about 50-80% by weight, the content of the magnesium stearate is about 1-5% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 5:1 to 1:5;
most preferably, the content of the active ingredient is about 12-16% by weight, the content of the croscarmellose sodium is about 6-10% by weight, the content of the sodium hydrogencarbonate is about 2-5% by weight, the content of the mannitol is about 65-78% by weight, and the content of the magnesium stearate is about 2-4% by weight.

### Claim 10 (depends on 1)

Use of the oral solid preparation or tablet according to claim 1 for preparation of an angiotensin II receptor antagonist, or for preparation of a medicament for preventing and/or treating hypertension, chronic heart failure, diabetic nephropathy.

### Claim 11 (depends on 2)

The oral solid preparation according to claim 2, wherein,
a content of the active ingredient is about 5-50% by weight, a content of the disintegrant is about 1-20% by weight, a content of the disintegrant assistant is about 0.1-35% by weight, a content of the excipient is about 20-80% by weight, a content of the lubricant is about 0.25-10% by weight, and a weight ratio of the disintegrant to the disintegrant assistant is from 10:1 to 1:10;
preferably, the content of the active ingredient is about 8-30% by weight, the content of the disintegrant is about 2-18% by weight, the content of the disintegrant assistant is about 0.5-30% by weight, the content of the excipient is about 30-80% by weight, the content of the lubricant is about 0.5-8% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 8:1 to 1:8;
further preferably, the content of the active ingredient is about 10-20% by weight, the content of the disintegrant is about 4-15% by weight, the content of the disintegrant assistant is about 1-25% by weight, the content of the excipient is about 50-80% by weight, the content of the lubricant is about 1-5% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 5:1 to 1:5;
further preferably, the content of the active ingredient is about 12-16% by weight, the content of the disintegrant is about 6-10% by weight, the content of the disintegrant assistant is about 2-5% by weight, the content of the excipient is about 65-78% by weight, and the content of the lubricant is about 2-4% by weight;
more preferably, the oral solid preparation is a tablet.

### Claim 12 (depends on 3)

The oral solid preparation according to claim 3, wherein,
a content of the active ingredient is about 5-50% by weight, a content of the disintegrant is about 1-20% by weight, a content of the disintegrant assistant is about 0.1-35% by weight, a content of the excipient is about 20-80% by weight, a content of the lubricant is about 0.25-10% by weight, and a weight ratio of the disintegrant to the disintegrant assistant is from 10:1 to 1:10;
preferably, the content of the active ingredient is about 8-30% by weight, the content of the disintegrant is about 2-18% by weight, the content of the disintegrant assistant is about 0.5-30% by weight, the content of the excipient is about 30-80% by weight, the content of the lubricant is about 0.5-8% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 8:1 to 1:8;
further preferably, the content of the active ingredient is about 10-20% by weight, the content of the disintegrant is about 4-15% by weight, the content of the disintegrant assistant is about 1-25% by weight, the content of the excipient is about 50-80% by weight, the content of the lubricant is about 1-5% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 5:1 to 1:5;
further preferably, the content of the active ingredient is about 12-16% by weight, the content of the disintegrant is about 6-10% by weight, the content of the disintegrant assistant is about 2-5% by weight, the content of the excipient is about 65-78% by weight, and the content of the lubricant is about 2-4% by weight;
more preferably, the oral solid preparation is a tablet.

### Claim 13 (depends on 3)

A tablet comprising a crystalline form I, a crystalline form II or a mixture thereof in any ratio as an active ingredient, mannitol as an excipient, croscarmellose sodium as a disintegrant, sodium hydrogencarbonate as a disintegrant assistant, and magnesium stearate as a lubricant;
wherein the crystalline form I and the crystalline form II are defined according to claim 3;
preferably, a content of the active ingredient is about 5-50% by weight, a content of the croscarmellose sodium is about 1-20% by weight, a content of the sodium hydrogencarbonate is about 0.1-35% by weight, a content of the mannitol is about 20-80% by weight, a content of the magnesium stearate is about 0.25-10% by weight, and a weight ratio of the disintegrant to the disintegrant assistant is from 10:1 to 1:10;
further preferably, the content of the active ingredient is about 8-30% by weight, the content of the croscarmellose sodium is about 2-18%, the content of the sodium hydrogencarbonate is about 0.5-30% by weight, the content of the mannitol is about 30-80% by weight, and the content of the magnesium stearate is about 0.5-8% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 8:1 to 1:8;
more preferably, the content of the active ingredient is about 10-20% by weight, the content of the croscarmellose sodium is about 4-15% by weight, the content of the sodium hydrogencarbonate is about 1-25% by weight, the content of the mannitol is about 50-80% by weight, the content of the magnesium stearate is about 1-5% by weight, and the weight ratio of the disintegrant to the disintegrant assistant is from 5:1 to 1:5;
most preferably, the content of the active ingredient is about 12-16% by weight, the content of the croscarmellose sodium is about 6-10% by weight, the content of the sodium hydrogencarbonate is about 2-5% by weight, the content of the mannitol is about 65-78% by weight, and the content of the magnesium stearate is about 2-4% by weight.

### Claim 14 (depends on 2)

Use of the oral solid preparation or tablet according to claim 2 for preparation of an angiotensin II receptor antagonist, or for preparation of a medicament for preventing and/or treating hypertension, chronic heart failure, diabetic nephropathy.

### Claim 15 (depends on 3)

Use of the oral solid preparation or tablet according to claim 3 for preparation of an angiotensin II receptor antagonist, or for preparation of a medicament for preventing and/or treating hypertension, chronic heart failure, diabetic nephropathy.

### Claim 16 (depends on 4)

Use of the oral solid preparation or tablet according to claim 4 for preparation of an angiotensin II receptor antagonist, or for preparation of a medicament for preventing and/or treating hypertension, chronic heart failure, diabetic nephropathy.

### Claim 17 (depends on 5)

Use of the oral solid preparation or tablet according to claim 5 for preparation of an angiotensin II receptor antagonist, or for preparation of a medicament for preventing and/or treating hypertension, chronic heart failure, diabetic nephropathy.

### Claim 18 (depends on 6)

Use of the oral solid preparation or tablet according to claim 6 for preparation of an angiotensin II receptor antagonist, or for preparation of a medicament for preventing and/or treating hypertension, chronic heart failure, diabetic nephropathy.

### Claim 19 (depends on 7)

Use of the oral solid preparation or tablet according to claim 7 for preparation of an angiotensin II receptor antagonist, or for preparation of a medicament for preventing and/or treating hypertension, chronic heart failure, diabetic nephropathy.

### Claim 20 (depends on 8)

Use of the oral solid preparation or tablet according to claim 8 for preparation of an angiotensin II receptor antagonist, or for preparation of a medicament for preventing and/or treating hypertension, chronic heart failure, diabetic nephropathy.
